EUVIMEDEUVIMED entdecken
Crossref

SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway

Yu-Jeong Choi, Yoon Hey Chung, Kangwook Lee, Miso Jeong, Seong-Gyu Ko

Anticancer Research · 2024

DOI: 10.21873/anticanres.16992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yu-Jeong Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Imidazoles, Lung Neoplasms, Oximes. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafImidazolesLung NeoplasmsOximesMutationMAP Kinase Signaling SystemXenograft Model Antitumor AssaysHumansAnimalsMiceCell Line, TumorApoptosisAntineoplastic Combined Chemotherapy ProtocolsCell ProliferationDrug Synergism

Stichwörter der Autor:innen

DabrafenibNSCLCNon-V600E BRAF mutationSH003combination treatment

Substanzen

dabrafenibProto-Oncogene Proteins B-rafImidazolesOximesBRAF protein, human

Autor:innen und Institutionen

  • Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Food and Biotechnology, Korea University, Sejong, Republic of Korea.
  • Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
  • Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea; epiko@khu.ac.kr.

Zitieren

APA

Choi, Y. J., Chung, Y. H., Lee, K., Jeong, M., & Ko, S. G. (2024). SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway. Anticancer Research. https://doi.org/10.21873/anticanres.16992

Vancouver

Choi YJ, Chung YH, Lee K, Jeong M, Ko SG. SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway. Anticancer Research. 2024. doi:10.21873/anticanres.16992

BibTeX
@article{Choi2024,
  author = {Choi, Yu-Jeong and Chung, Yoon Hey and Lee, Kangwook and Jeong, Miso and Ko, Seong-Gyu},
  title = {SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16992}
}
Kostenlos starten →